文献速递系统性红斑狼疮

SLE中DN2 B细胞CD72下调与疾病活动及利妥昔单抗耐药相关

CD72 downregulation on DN2 B cells is associated with disease activity and resistance to rituximab in systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

活动期SLE患者CD72阴性B细胞在SWM、aNAV、DN2和PB亚群增多,CD72阴性DN2细胞与LN、抗dsDNA阳性、SLEDAI-2K正相关、C3负相关,且对利妥昔单抗相对抵抗。

要点

  • 活动期SLE患者CD72阴性B细胞在SWM、aNAV、DN2和PB亚群频率升高
  • CD72阴性DN2细胞在狼疮肾炎患者中增多,且高表达CD95、低表达CD20
  • CD72阴性DN2频率与SLEDAI-2K正相关、与C3负相关,抗dsDNA阳性者升高

核心结论

  • SLE中DN2 B细胞CD72表达降低,与抗dsDNA阳性、补体消耗及BCR下游信号增强相关。
  • CD72阴性B细胞对利妥昔单抗相对抵抗,提示检查点程序受损可能参与疾病复发。

研究设计与样本

  • 采用光谱流式细胞术分析B细胞表型,并通过体外BCR刺激后下游磷酸化研究信号传导。

主要发现

  • 活动期SLE患者较健康对照在SWM、aNAV、DN2和PB亚群中CD72阴性B细胞频率增加。
  • CD72阴性DN2细胞(CD27-IgD-CD21-CD11c+)在狼疮肾炎患者中升高,且较健康对照和经典SLE DN2细胞表达更高CD95和更低CD20。
  • BCR刺激后,狼疮CD72阴性SWM和DN2 B细胞较CD72阳性对应细胞及总体细胞群显示pSYK磷酸化增加。
  • CD72阴性DN2频率与SLEDAI-2K正相关、与C3水平负相关,并在抗dsDNA阳性患者中升高。
  • 利妥昔单抗治疗后3个月,残留DN2细胞主要为CD72阴性。

临床怎么用

  • CD72阴性DN2 B细胞频率或可辅助评估SLE疾病活动及利妥昔单抗治疗后复发风险。
  • 抗dsDNA阳性、补体消耗的SLE患者中CD72阴性DN2细胞增多,需关注其治疗抵抗可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In SLE, expanded B cell subtypes like double-negative 2 (DN2) may harbour autoreactivity, which may be linked to impaired checkpoint regulation. We investigated checkpoint molecule CD72 on B cells, its clinical associations, and dynamic changes upon rituximab (RTX) treatment. METHODS: Thirty SLE patients (26 with active disease) were studied. Seven received RTX treatment with sampling at baseline, 3 months and 6 months. B cell phenotypes were analysed using spectral flow cytometry, and clinical associations were evaluated. B cell receptor (BCR) signalling was studied through downstream phosphorylation in vitro. RESULTS: Patients with active SLE showed increased frequencies of CD72-negative B cells in switched memory (SWM), activated naïve (aNAV), DN2 and plasmablast (PB) subsets compared with healthy controls (HCs). CD72-negative DN2 cells (CD27-IgD-CD21-CD11c+) were elevated in LN patients. These cells expressed higher CD95 and lower CD20 compared with HCs and canonical SLE DN2. Upon BCR stimulation, lupus CD72-negative SWM and DN2 B cells displayed increased pSYK phosphorylation compared with their CD72-positive counterparts and the overall cell population. CD72-negative DN2 frequencies associated positively with SLEDAI-2K and inversely with C3 levels and were increased in anti-dsDNA-positive patients. After RTX treatment, the remaining DN2 cells were primarily CD72-negative at 3 months. CONCLUSION: The DN2 B cell subset have been associated with autoimmunity. We showed that DN2 B cells in SLE have reduced CD72 expression, which is associated with anti-dsDNA positivity, complement consumption, and enhanced BCR downstream signalling. The relative resistance of CD72-negative B cells to RTX indicates that an impaired checkpoint programme in lupus B cells may potentially contribute to disease relapse. These findings require validation in larger cohorts.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Wangriatisak K, Huang W, Sechi G, et al. CD72 downregulation on DN2 B cells is associated with disease activity and resistance to rituximab in systemic lupus erythematosus. Rheumatology (Oxford). 2026. PMID: 41738264. doi:10.1093/rheumatology/keag097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。